Townsquare Capital LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Townsquare Capital LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 12,386 shares of the medical equipment provider’s stock, valued at approximately $1,108,000.

Other institutional investors and hedge funds have also modified their holdings of the company. HighTower Advisors LLC acquired a new stake in Lantheus during the 3rd quarter worth $607,000. MML Investors Services LLC grew its stake in shares of Lantheus by 24.6% during the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider’s stock worth $476,000 after purchasing an additional 857 shares during the period. World Investment Advisors LLC bought a new stake in Lantheus in the third quarter valued at about $60,000. Wilmington Savings Fund Society FSB acquired a new position in Lantheus in the third quarter valued at about $25,000. Finally, Tidal Investments LLC boosted its holdings in Lantheus by 25.2% during the third quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock worth $1,934,000 after buying an additional 3,547 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock worth $6,016,046 over the last ninety days. Insiders own 1.50% of the company’s stock.

Lantheus Trading Up 0.8 %

Lantheus stock opened at $101.32 on Friday. Lantheus Holdings, Inc. has a 1-year low of $61.47 and a 1-year high of $126.89. The company has a market cap of $6.94 billion, a P/E ratio of 16.86 and a beta of 0.20. The company has a fifty day simple moving average of $95.00 and a 200 day simple moving average of $95.55.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.